Understanding SARS-CoV-2 and Host Immune Response to COVID-19 with PacBio Sequencing

For Research Use Only. Not for use in diagnostics procedures.
© Copyright 2020 by Pacific Biosciences of California, Inc. All rights reserved. 
1305 O'Brien Rd., Menlo Park, CA 94025   |  Legal & Trademarks

By registering on this web page, you are consenting and agreeing to collection and use of that information by PacBio in accordance with its Privacy Policy.

With the COVID-19 global pandemic, there is an urgent need to advance genetic research into the novel coronavirus (SARS-CoV-2), including testing, transmission, treatment, and the immunology and epidemiology of host immune response.   

Highly accurate long-read sequencing provides multiple benefits for COVID-19 research, including full-length viral RNA reference genomes for SARS-CoV-2 isolates.
 

Join us to hear directly from research scientists discussing these long-read sequencing applications — including methods, case study results, and new assays for SARS-CoV-2 and COVID-19 that are now under development.


Attend this webinar to understand:

  • How highly accurate long reads can help with sequencing SARS-CoV-2
     
  • Protocols for genetic mutation profiling in SARS-CoV-2 viral RNA isolates
     
  • The advantages of long-read sequencing for BCR profiling and inference-free genotyping of the IGH locus for understanding variation in antibody-mediated immunty, which may be of relevance to the current pandemic
     
  • Methods for imputation-free long-read sequencing of the HLA loci, highly polymorphic mediators of the human adaptive immune response that have been linked to increased resistance or susceptibility to infectious diseases

WATCH THE WEBINAR

Melissa Laird-Smith, Ph.D. 
Assistant Professor of Genetics and Genome Sciences
Mt. Sinai


Talk: Evaluating the Impact of Host Immune Restriction in Health and Disease with High Resolution HLA Typing

SPEAKERS:

Corey T. Watson, Ph.D.
Assistant Professor
University of Louisville School of Medicine


Talk: Overcoming Complexity to Elucidate the Role of IGH Haplotype Diversity in Antibody-mediated Immunity

Meredith Ashby, Ph.D.
Director, Market Strategy for Microbial and Cancer Genomics
PacBio

HOSTED BY